Laura Joszt
Vice President of Content at Pharmacy Times
Vice President of Content at American Journal of Managed Care
Vice President of Content at MJH Life Sciences
Vice President of Content at Chief Healthcare Executive
Editorial Director for @AJMC_Journal at @MJHLifeSciences
Articles
-
2 days ago |
ajmc.com | Laura Joszt |Coral Omene
In value-based cancer care, insurance hurdles can create administrative burdens that cause anxiety for patients and providers and delay essential treatments or divert from optimal patient care, said Coral Omene, MD, PhD, associate professor, Robert Wood Johnson Medical School. This transcript has been lightly edited; captions were auto-generated.
-
3 days ago |
ajmc.com | Laura Joszt
For adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), there are critical disparities in outcomes and unmet needs for later-line treatments, according to posters presented at the 2025 annual meeting of the American Society of Clinical Oncology. One poster delved into the overall survival (OS) rates by race/ethnicity, while the other evaluated the percentage of AYA patients who relapse and need treatment in the third-line setting.
-
1 week ago |
ajmc.com | Laura Joszt |Eileen Peng
In value-based care models, pharmacists play an important role in multidisciplinary team care in selecting cost-effective treatments and managing adherence to prevent hospitalizations and emergency department (ED) visits, explained Eileen Peng, PharmD, vice president, chief administrator, and pharmacy officer, Astera Cancer Care. This transcript has been lightly edited; captions were auto-generated.
-
1 week ago |
ajmc.com | Laura Joszt
Artificial intelligence (AI) can be used to accurately adjust insulin doses for patients with type 2 diabetes (T2D) in an inpatient setting, according to the results of a study published in JAMA Network Open.1 The AI-powered system was able to match the doctors’ dosing to keep blood sugar within the target range, providing a safe, time-saving method.
-
1 week ago |
businessandamerica.com | Laura Joszt
Novel therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have led to an evolution in the role of the pharmacist in care teams for patients with cancer, explained Eileen Peng, PharmD, vice president, chief administrator, and pharmacy officer, Astera Cancer Care. Their jobs are no longer purely a dispensing role but instead encompass patient selection and management of adverse effects.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 324
- Tweets
- 2K
- DMs Open
- No
RT @Michael_Chernew: It’s awards night in Nashville. Congrats to @IshaniG on winning the 2022 @AJMC_Journal Seema Sonnad Emerging Leader in…
Alzheimer Disease Drug Lecanemab Successfully Reduces Cognitive, Functional Decline https://t.co/zKtFQBEvku via @AJMC_Journal https://t.co/U4DZRlD3kj
FDA Advisory Committee Gives Positive Vote for Microbiota-based C. Diff Therapy https://t.co/sdopevbiYn via @denise_myshko https://t.co/dHHUble7Q7